Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-20T02:31:23.087Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in france, germany and belgium – a retrospective database study

Published online by Cambridge University Press:  13 August 2021

R. Cai ,
F. Decuypere ,
P. Chevalier ,
A. Wimmer ,
P. Guillon ,
S. Pype ,
A. Godet  and
V. Timtschenko
R. Cai*
Affiliation:
Real World Evidence, IQVIA, Zaventem, Belgium
F. Decuypere
Affiliation:
Analytics Solutions, IQVIA, Zaventem, Belgium
P. Chevalier
Affiliation:
Real World Evidence, IQVIA, Zaventem, Belgium
A. Wimmer
Affiliation:
Medical Affairs, Janssen-Cilag, Neuss, Germany
P. Guillon
Affiliation:
Health Economics, Janssen-Cilag, Issy-les-Moulineaux, France
S. Pype
Affiliation:
Medical Advisor, Janssen-Cilag, Beerse, Belgium
A. Godet
Affiliation:
Health Economics, Janssen-Cilag, Issy-les-Moulineaux, France
V. Timtschenko
Affiliation:
Medical Affairs, Janssen-Cilag, Neuss, Germany
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients.

Objectives

To assess risk factors of treatment discontinuation in patients on paliperidone palmitate and risperidone microsphere. Additionally, treatment continuation between patients with PP1M and PP3M was compared.

Methods

The IQVIA Longitudinal Prescription databases were used. Risk factors of treatment discontinuation were identified by a multilevel survival regression using Cox proportional hazards model. Kaplan Meier analyses were performed by identified significant risk factors.

Results

25,361 patients (France: 9,720; Germany: 14,461; Belgium: 1,180) were included. Over a one-year follow-up period, a significant higher treatment continuation was observed for patients newly initiated on paliperidone palmitate (46.2%) than those initiated on risperidone microspheres (14.6%). Additionally, a significantly higher treatment continuation was found for ‘stable’ PP3M patients (81.8%) than ‘stable’ PP1M patients (62.9%). Patients were more likely to discontinue when drugs prescribed by GP only (HR = 1.68, p < 0.001 vs. psychiatrist only) or being females (HR = 1.07, p < 0.001), whereas discontinuation rate decreased with age (31-50 years: HR = 0.95, p = 0.006 and > 50 years: HR = 0.91, p < 0.001 vs. 18-30 years).

Conclusions

Paliperidone palmitate was associated with a significantly higher treatment continuation than risperidone microspheres. Treatment continuation is likely to be improved by targeting young patients (18-30 years), empowering GPs with mental health knowledge and managing patients by a collaborative primary care-mental health model. Further research is needed to understand why females have more treatment discontinuation.

Disclosure

Rui Cai, Flore Decuypere and Pierre Chevalier are IQVIA employees and served as paid consultants to Janssen during the conduct of this study. Antonie Wimmer, Pascal Guillon, Stefan Pype, Annabelle Godet, Valeria Timtschenko are Janssen employees.

Keywords

antipsychoticsPP1MPP3Mrisperidone microspheretreatment continuation
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S164
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.